All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Proteasome inhibitors bind to the proteasome and prevent degradation of proteins involved in various signaling cascades. Preclinical studies in AML indicate proteasome inhibition disrupts proliferative cell signaling pathways, has cytotoxic synergism with other chemotherapies, and induces autophagy. For example, in AML, bortezomib is being investigated with combination chemotherapy regimens.